ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

アセナピン

5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate

HCID 11954293
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
65576-45-6
標準SMILES
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O
InChIKey
GMDCDXMAFMEDAG-BTJKTKAUSA-N
分子式
C21H20ClNO5
平均分子量
401.8 g/mol
単同位体質量
401.1030004

概要

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

名称と識別子

優先名称
5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate
IUPAC
(Z)-but-2-enedioic acid;9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
現地名
アセナピン
英語名
Asenapine
分子式
C17H16ClNO
分子量
285.77

名称と別名

SCHEMBL6029138CHEMBL3544974SCHEMBL29374126GMDCDXMAFMEDAG-BTJKTKAUSA-NHMS5079P05EBC-26957DB06216EN300-16929915-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate(2Z)-but-2-enedioic acid; 9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.0^{2,6}.0^{7,12}]octadeca-1(14),7(12),8,10,15,17-hexaeneアセナピンrel-5-クロロ-2,3,3aα*,12bβ*-テトラヒドロ-2-メチル-1H-ジベンゾ[2,3:6,7]オキセピノ[4,5-c]ピロール
名称をさらに表示
SaphrisAsenapine Impurity 2HSDB8061AsenapineHSDB 8061HSDB-8061(±)-AsenapineUnii-jkz19V908oEinecs 265-829-4Asenapine [inn:ban]

データベース識別子

物性

構造計算による物性

極性表面積
87.1 Ų
水素結合供与体数
2
水素結合受容体数
6
回転可能結合数
2
重原子数
28
形式電荷
0
複雑度
482

物理化学的性質

沸点
357.9 · 357.9±42.0 °C(Predicted)
比重(密度)
1.231 · 1.231
貯蔵温度
4 °C · Store at +4°C
溶解性
50 · DMSO:50.0(Max Conc. mg/mL);174.97(Max Conc. mM)
外見
A solid
酸解離定数(Pka)
9.5 · 9.50±0.20(Predicted)
色
White to off-white

化学的性質

化学的特性Yellow Oil

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全データ

有毒物質データの
65576-45-6(Hazardous Substances Data)

化学と産業

薬理情報

Protein Binding95% protein bound
Pharmacodynamics · 1 件

Asenapine is a serotonin, dopamine, noradrenaline, and histamine antagonist in which asenapine possess more potent activity with serotonin receptors than dopamine. Sedation in patients is associated with asenapine's antagonist activity at histamine receptors. Its lower incidence of extrapyramidal effects are associated with the upregulation of D1 receptors. This upregulation occurs due to asenapine's dose-dependent effects on glutamate transmission in the brain. It does not have any significant activity with muscarinic, cholinergic receptors therefore symptoms associated with anticholinergic drug activity like dry mouth or constipation are not expected to be observed. Asenapine has a higher affinity for all aforementioned receptors compared to first-generation and second-generation antipsychotics except for 5-HT1A and 5-HT1B receptors.

Mechanism of Action · 1 件

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia.

Biological Half-Life24 hours (range of 13.4 - 39.2 hours)
Metabolism/MetabolitesAsenapine is oxidized via CYP1A2 and undergoes direct glucuronidation via UGT1A4. Oxidation via CYP1A2 is asenapine's primary mode of metabolism.
Absorption, Distribution and Excretion · 3 件

Cmax, single 5 mg dose = 4 ng/mL (within 1 hour); Bioavailability, sublingual administration = 35%; Bioavailability, oral administration (swallowed) = <2%; Time to steady state, 5 mg = 3 days; Peak plasma concentration occurs within 0.5 to 1.5 hours. Doubling dose of asenapine results in 1.7-fold increase in maximum concentration and exposure. Drinking water within 2-5 minutes post administration of asenapine results in a decrease in exposure.

Urine (50%) and feces (50%)

関連反応

5 件
反応記録を作成
HRID 63779 の反応式
HRID 63779反応物として
HRID 63782 の反応式
HRID 63782生成物として
HRID 1625165 の反応式
HRID 1625165生成物として
HRID 1625166 の反応式
HRID 1625166生成物として
HRID 1625169 の反応式
HRID 1625169生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
CAS
65576-45-6
PubChem CID
11954293
ChEMBL
CHEMBL3544974

20-25 L/kg

応用分野 · 2 件

説明(±)-Asenapine is an atypical antipsychotic. It binds to dopamine D1-4, α-adrenergic, and histamine receptors (Kis = 0.42-1.45, 0.32-1.26, and 1-6.17 nM, respectively), as well as the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and 5-HT7 (Kis = 0.03-3.98 nM). (±)-Asenapine inhibits the suppression of neuron firing induced by the 5-HT2A, dopamine D2, and α2-adrenergic receptor agonists 2,5-dimethoxy-4-iodoamphetamine (DOI), apomorphine, and clonidine , respectively, in rat brain (ED50s = 75, 40, and 85 μg/kg, respectively). In vivo, (±)-asenapine (0.05-0.2 mg/kg, s.c.) increases extracellular dopamine levels in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), and lateral striatum and suppresses the conditioned avoidance response in rats. It prevents acute and chronic phencyclidine-induced deficits in cued reversal learning in rats when administered at a dose of 0.075 mg/kg. Formulations containing asenapine have been used in the treatment of schizophrenia and bipolar I disorder.

使用Combined serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related to Mianserin. Antipsychotic

上流・下流製品情報

上流原料

アセナピンマレイン酸塩trans-(+/-)-11-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one2-クロロフェニル酢酸